These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37579117)

  • 1. "Macrodosing" Sublingual Buprenorphine and Extended-release Buprenorphine in a Hospital Setting: 2 Case Reports.
    Kahan M; Marion-Bellemare L; Samson J; Srivastava A
    J Addict Med; 2023 Jul-Aug 01; 17(4):485-487. PubMed ID: 37579117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
    Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
    JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method.
    Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR
    J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose buprenorphine for treatment of high potency opioid use disorder.
    Danilewitz M; McLean M
    Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
    Coish R; Hardial J
    J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.
    Azar P; Schneiderman H; Barron H; Wong JSH; Meyer M; Newman-Azar D; Narimani M; Ignaszewski MJ; Mathew N; Mullen R; Krausz RM; Maharaj AR
    Addict Sci Clin Pract; 2024 Jun; 19(1):50. PubMed ID: 38886826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
    Antoine D; Huhn AS; Strain EC; Turner G; Jardot J; Hammond AS; Dunn KE
    Am J Addict; 2021 Jan; 30(1):83-87. PubMed ID: 32572978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precipitated Opioid Withdrawal Treated With Ketamine in a Hospitalized Patient: A Case Report.
    Christian NJ; Butner JL; Evarts MS; Weimer MB
    J Addict Med; 2023 Jul-Aug 01; 17(4):488-490. PubMed ID: 37579118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 10. Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations.
    Bhatia G; Sarkar S
    Asian J Psychiatr; 2020 Oct; 53():102121. PubMed ID: 32460142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.
    Shearer D; Young S; Fairbairn N; Brar R
    Drug Alcohol Rev; 2022 Feb; 41(2):444-448. PubMed ID: 34647379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of buprenorphine + naloxone sublingual tablet in the treatment of neonatal opioid withdrawal syndrome: Two case reports.
    Ulu E; Kandeğer A; Meriç R
    J Addict Dis; 2022; 40(3):432-438. PubMed ID: 34775907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
    Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
    Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of buprenorphine-precipitated withdrawal managed with high-dose buprenorphine.
    Quattlebaum THN; Kiyokawa M; Murata KA
    Fam Pract; 2022 Mar; 39(2):292-294. PubMed ID: 34173647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film.
    Gunderson EW; Sumner M
    J Addict Med; 2016; 10(2):124-30. PubMed ID: 26918662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Extended Release Buprenorphine Injection to Discontinue Sublingual Buprenorphine: A Case Series.
    Ritvo AD; Calcaterra SL; Ritvo JI
    J Addict Med; 2021 May-Jun 01; 15(3):252-254. PubMed ID: 32925232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful rotation from long-acting full agonist opioids to sublingual buprenorphine/naloxone using a microdosing approach.
    Vytialingam RC; Schug SA; O'Regan R
    J Opioid Manag; 2021; 17(7):159-166. PubMed ID: 34520037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of kratom dependence with buprenorphine/naloxone in a veteran population.
    Lei J; Butz A; Valentino N
    Subst Abus; 2021; 42(4):497-502. PubMed ID: 33617752
    [No Abstract]   [Full Text] [Related]  

  • 20. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.